Navigation Links
2-step immunotherapy attacks advanced ovarian cancer
Date:1/31/2013

PHILADELPHIA -- Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the trial responded to the therapy, the investigators report this month in OncoImmunology.

"What we proved in this study is that this is a safe treatment strategy," says co-first author Lana Kandalaft, PharmD, MTR, PhD, research assistant professor of Obstetrics and Gynecology and director of clinical development in the Ovarian Cancer Research Center. "It is a walk in the park for patients, especially compared to standard chemotherapies and surgical treatments for ovarian cancer literally, some patients left the clinic and went for a walk in a nearby park after their treatment."

The findings follow research by the study's senior author, George Coukos, MD, PhD, director of the Ovarian Cancer Research Center at Penn, who showed in 2003 that women whose ovarian tumors were infiltrated by healthy immune cells, called T cells, tended to live longer than women whose tumors were devoid of T cells. That observation and other subsequent ones suggest the patient's immune system is trying to fight off the disease but can't quite muster the strength to beat it. Therefore, investigators have been trying to find ways using patients' own tumor cells to boost the immune system's power.

In the current study, Coukos, Kandalaft, co-first author Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, and colleagues treated six women with advanced ovarian cancer in a two-staged immunotherapy protocol in which they utilized a d
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. Immunotherapy reduces allergic patients sensitivity to peanuts
3. Sublingual immunotherapy shows promise as treatment for peanut allergy
4. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
5. Antibodies reverse type 1 diabetes in new immunotherapy study
6. Immunotherapy for elderly cancer patients finds new promise in drug combination
7. Toward a better cyanide antidote for terrorist attacks and other mass casualty events
8. New Guidelines Seek to Streamline Care for Worst Heart Attacks
9. Penn research reveals new aspect of platelet behavior in heart attacks: Clots can sense blood flow
10. Study Tallies Economic Fallout From Workers Heart Attacks
11. Decline in incidence of heart attacks appears associated with smoke-free workplace laws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 One in ... according to research presented today at the American Orthopaedic ... The study examined the long term success of surgery ... “We examined survey data from 242 patients who underwent ... Justin P. Roe, MBBS, FRACS, from North Sydney Orthopaedic ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... -- Preliminary results from the first-of-its-kind Clinical Evaluation ... today at the Society of Gastroenterology Nurses and Associates, ... The study indicated that while there are written ... participated in the study, significant variation in manual reprocessing ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... Alcon and Initial Payments from New Galderma Collaboration ... May 18 NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class anti-infective products for the treatment and ... causing resistance, reported today its financial results and ...
... Dad and Give Back To A Worthy CauseLOS ANGELES , ... figures in their lives and Teleflora, the world,s leading ... run with its Father,s Day product line-up. Adding extra batting ... Prostate Cancer Foundation (PCF), to help raise awareness for prostate cancer ...
... - New data to be presented on Abbott,s market-leading ... Abbott,s next-generation drug eluting stent in developmentBARCELONA, Spain, May ... announced the company,s schedule of major events and news ... 22. These include the presentation of new data from ...
Cached Medicine News:Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 2Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 3Health News:Abbott Announces EuroPCR 2009 Activities 2Health News:Abbott Announces EuroPCR 2009 Activities 3Health News:Abbott Announces EuroPCR 2009 Activities 4
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
(Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused ... (TLR8) candidates for the treatment of cancer, respiratory ... randomized, placebo controlled clinical trial evaluating VTX-1463 for ... that VTX-1463 significantly improved allergy symptoms based on ...
... R.I., Oct. 7 CVS Caremark ... it has appointed Jonathan C. Roberts as Chief ...  Roberts, who is currently Executive Vice President, Rx ... assume the leadership of PBM operations, mail service ...
Cached Medicine Technology:VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2CVS Caremark Appoints Jonathan C. Roberts as PBM Chief Operating Officer 2
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... Save precious time and gain efficiency ... Lab Automation System (LAS), the high-throughput ... sample-processing capabilities. The Olympus OLA2500 LAS ... designed for medium- to high-volume laboratories. ...
The Freedom EVO series platform offers a choice of flexible, scalable solutions for current and future application needs....
Medicine Products: